Latest Articles in torrent pharma
Torrent Pharma Says Nothing To Disclose On Cipla Stake Buyout
India's Torrent Pharmaceuticals on Friday said it has no information requiring disclosure under listing regulations after the Economic Times reported that it was in talks to buy out the stake of rival Cipla's top shareholders
Read More
Torrent Pharma's Profit Picks Up By 6% In Q1 Results
Torrent Pharma reported its quarter-one earnings on Monday, the pharma major has recorded sales worth Rs 2,591 crores for the quarter that ended in June 2023, a 10 per cent rise over the same quarter in the previous year
Read More
Torrent Pharma Posts Net Profit Of Rs 287 Cr, Sales Up By 17% In Q4FY23
Ahmedabad-based Indian pharmaceutical major Torrent Pharmaceutical on Tuesday posted its financials for the fourth quarter and full year ending March 31, 2023. The company posted a net profit of Rs 287 crores in the January-March quarter against a net loss of Rs 188 crores recorded in Q4 last year
Read More
Torrent Pharma's Gujarat Facility Gets OAI Status From USFDA
The manufacturing site was first inspected on September 28, 2022, and was issued Form 483 with three observations by the top US Health regulator flagging quality as well as procedural lapses at the facility
Read More
Torrent Pharma Reports Sales Of Rs 2,291 Cr, PAT Down By 1% YoY In Sept Quarter
The pharma company’s net profit slumped by 1 per cent year on year (YoY) and stood at Rs 312 crores in the second quarter from Rs 316 crores in the previous year
Read More
Torrent Pharma Set To Aquire Curatio Healthcare
The consideration includes Rs. 115 crores (on the date of signing) of cash and cash equivalents in the acquired business indicating an Enterprise Value of Rs. 1,885 crores, the company said in a statement on Tuesday
Read More
Torrent Pharma Enters Into Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19 in India
Under the agreement, Lilly has provided the license to manufacture and distribute Baricitinib to Torrent for India along with Lilly's other license partners.
Read More